Synapse - Heiko Schoder

Results (128)

FDG-PET in the staging and prognosis of T-cell lymphoma

Meeting Abstract

Casulo, C.; Maragulia, J.; Zelenetz, A. D.; Schöder, H.; Feeney, J.; Horwitz, S. M.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Six cycles of ABVD and a negative PET scan negates the need for radiologic follow-up in early stage, non-bulky Hodgkin lymphoma: MSKCC retrospective analysis

Meeting Abstract

Hartridge-Lambert, S. K.; Schoder, H.; Lim, R. C.; Maragulia, J. C.; Portlock, C. S.
Blood (2011)

Fulltext@MSK | Save

Risk-adapted therapy using biopsy confirmation of abnormal interim FDG-PET for patients with advanced stage diffuse large B cell lymphoma (DLBCL), and exploratory evaluation of FLT-PET

Meeting Abstract

Moskowitz, C. H.; Schoder, H.; Hamlin, P. A.; Gerecitano, J. F.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M.; Portlock, C. S.; more...
Annals of Oncology (2011)

Fulltext@MSK | Save

FDG-PET in the staging and prognosis of T-cell lymphoma

Meeting Abstract

Casulo, C.; Maragulia, J.; Zelenetz, A.; Schoder, H.; Feeney, J.; Horwitz, S.
Annals of Oncology (2011)

Fulltext@MSK | Save

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: Pretreatment prognostic factors and interim PET

Journal Article

Straus, D. J.; Johnson, J. L.; LaCasce, A. S.; Bartlett, N. L.; Kostakoglu, L.; Hsi, E. D.; Schoder, H.; Hall, N. C.; Jung, S. H.; Canellos, G. P.; more...
Blood (2011)

Fulltext@MSK | Save

Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma? - Reply